Company
Immusoft
Programming B Cells to Deliver Novel Therapies for Patients
Also known as IMMUSOFT CORP
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- IMMUSOFT CORP
Claim, correct or request removal
Record updated 28 September 2026
About
Our mission at Immusoft is to develop novel therapies, by programming B cells to produce therapeutic proteins that deliver functional improvement, to people living with rare and other diseases with significant unmet need.
Funding snapshot
- Total raised
- $40.5MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Grant, $15M2026-03-30
Funding rounds
- Grant
- $15M2026-03-30, Company stated
- Round, 2024
- $4.6M2024-05-28, SEC form D sold, 25 investors
- Round, 2020
- $10.3M2020-09-08, SEC form D sold, 32 investors
- Round, 2018
- $20.2M2018-01-04, SEC form D sold, 64 investors
- Round, 2016
- $2.7M2016-10-18, SEC form D sold, 11 investors
- Round, 2015
- $375K2015-08-03, SEC form D sold, 3 investors
- Round, 2014
- $2.4M2014-08-06, SEC form D sold, 11 investors
Products
- Other
- Immune System Programming (ISP™)
Loading relationship preview